PRCL-02

PRCL-02 is an orally administered small molecule inhibitor of the calcium release-activated calcium (CRAC) channel, specifically targeting the ORAI1 protein. It was initially developed by Madrigal Pharmaceuticals and later by PRCL Research. The drug acts as an immunomodulator by inhibiting store-operated calcium entry in lymphocytes, thereby suppressing T-cell proliferation and cytokine production. Preclinical studies have shown that it can suppress immune responses in models of organ transplantation and has been investigated for its potential to treat moderate to severe chronic plaque psoriasis. In clinical development, its highest reported phase is Phase 2 for psoriasis[1][2][4][3].